Gilead wants HIV drug patented
Business Standard|September 18, 2024
The Indian Patent Office is set to hear objections against patent claims filed by US-based pharmaceutical giant Gilead Sciences on HIV prevention drug "Lenacapavir".
ANJALI SINGH

Sankalp Rehabilitation Trust, a civil society organisation working with vulnerable populations, argues that the patent applications could impact access to affordable treatment in India and would hinder access to affordable generic versions of the drug.

On Thursday (September 19), the Indian Patent Office will hear objections filed by Sankalp against Gilead's applications, the organisation claimed.

Sankalp contends that Gilead's claims on Lenacapavir are not innovative and violate India's patent laws, which prevent the practice of "evergreening" extending monopolies on drugs through minor, unoriginal modifications.

هذه القصة مأخوذة من طبعة September 18, 2024 من Business Standard.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة September 18, 2024 من Business Standard.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BUSINESS STANDARD مشاهدة الكل
Low valuation sparks interest in IndusInd
Business Standard

Low valuation sparks interest in IndusInd

Analysts believe worst may be over for lender after sombre Q2 results

time-read
2 mins  |
November 13, 2024
Demand, margin gains ahead for UPL
Business Standard

Demand, margin gains ahead for UPL

Agrochemicals manufacturer UPL reported a muted quarter as operating profit remained flat on a year-on-year (Y-o-Y) basis, due to a price decline (down 7 percent Y-o-Y) and surplus capacity in China.

time-read
2 mins  |
November 13, 2024
Business Standard

Exchanges roll back direct payout of securities to client accounts

The National Stock Exchange (NSE) and BSE on Tuesday announced rollback of the direct payout of the securities to client demat accounts—which was enabled on November 11.

time-read
1 min  |
November 13, 2024
Swiggy makes market debut today
Business Standard

Swiggy makes market debut today

Shares of food delivery major Swiggy will make stock market debut on Wednesday following its ₹11,327 crore initial public offering (IPO), second biggest this year and sixth-largest to hit the domestic market.

time-read
1 min  |
November 13, 2024
NTPC Green Energy IPO eyes $12 bn Valuation
Business Standard

NTPC Green Energy IPO eyes $12 bn Valuation

NTPC Green Energy Ltd is considering seeking a valuation of about $12 billion in what could be one of India's biggest initial public offerings (IPO) in the renewable energy industry, according to people familiar with the matter.

time-read
1 min  |
November 13, 2024
Sebi simplifies process for registration of certain FPIs
Business Standard

Sebi simplifies process for registration of certain FPIs

Abridged version of application form to be available in 3 months

time-read
1 min  |
November 13, 2024
11 of 17 Nifty sector indices in correction mode
Business Standard

11 of 17 Nifty sector indices in correction mode

As many as 11 of 17 frontline Nifty sector indices are in 'correction' mode with energy, auto and central public sector enterprises (CPSE), consumption, and fast-moving consumer goods (FMCG) suffering the most in the recent market fall, according to data.

time-read
2 mins  |
November 13, 2024
Nifty falls to near 5-month low
Business Standard

Nifty falls to near 5-month low

Earnings disappointment and foreign outflows continue to weigh on markets

time-read
2 mins  |
November 13, 2024
BITING THE BULLET
Business Standard

BITING THE BULLET

The Bullet Train has been a 'dream project'. Can it become a reality anytime soon?

time-read
5 mins  |
November 13, 2024
Business Standard

India to be among top 3 or 4 mkts for Siemens in 3 years

Country now contributes 3.5-4% to the firm's revenue

time-read
2 mins  |
November 13, 2024